In a report released yesterday, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Aethlon Medical Inc (NASDAQ: AEMD), with a price target of $3. The company’s shares opened today at $1.30, close to its 52-week low of $0.79.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 2.3% and a 40.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Aethlon Medical Inc has an analyst consensus of Moderate Buy, with a price target consensus of $3.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.85 and a one-year low of $0.79. Currently, Aethlon Medical Inc has an average volume of 225.1K.
Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AEMD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aethlon Medical, Inc. is a therapeutic technology company, which focuses on addressing global health and biodefense needs. It develops Aethlon Hemopurifier, a medical device that targets the elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.
